At the time of writing, Zymeworks BC Inc [ZYME] stock is trading at $27.23, up 3.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZYME shares have gain 6.87% over the last week, with a monthly amount glided 20.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zymeworks BC Inc [NASDAQ: ZYME] stock has seen the most recent analyst activity on December 12, 2025, when Wells Fargo upgraded its rating to a Overweight but kept the price target unchanged to $33 for it. Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on December 03, 2025, and set its price target to $32. H.C. Wainwright upgraded its rating to a Buy but stick to its price target of $26 on October 14, 2025. B. Riley Securities initiated its recommendation with a Buy and recommended $30 as its price target on October 10, 2025. In a note dated December 16, 2024, JP Morgan upgraded an Overweight rating on this stock but restated the target price of $18.
For the past year, the stock price of Zymeworks BC Inc fluctuated between $9.03 and $28.49. Currently, Wall Street analysts expect the stock to reach $34.67 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $27.23 at the most recent close of the market. An investor can expect a potential return of 27.32% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
According to Zymeworks BC Inc [NASDAQ:ZYME], the company’s sales were 134.48M for trailing twelve months, which represents an 72.59% jump. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -207.35%, Pretax Profit Margin comes in at -171.28%, and Net Profit Margin reading is -183.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.24 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.65 points at the first support level, and at 26.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.59, and for the 2nd resistance point, it is at 27.94.
Ratios To Look Out For
It is important to note that Zymeworks BC Inc [NASDAQ:ZYME] has a current ratio of 6.94. In addition, the Quick Ratio stands at 6.94 and the Cash Ratio stands at 1.54. Considering the valuation of this stock, the price to sales ratio is 15.27, the price to book ratio is 6.44.
Transactions by insiders
Recent insider trading involved Derek John Michael Miller, Former Director, that happened on Nov 24 ’25 when 0.12 million shares were purchased. Former Director, Neil Gallagher completed a deal on Nov 21 ’25 to buy 0.1 million shares. Meanwhile, Director EcoR1 Capital, LLC bought 49502.0 shares on May 15 ’25.
